DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-988/S-024

Wyeth Pharmaceuticals, Inc.
Attn: Roberta Acchione, Associate Director
P.O. Box 8299
Philadelphia, PA 19101-8299

Dear Ms. Acchione:

Please refer to your supplemental new drug application dated December 3, 2004, received December 4, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Protonix® I.V. (pantoprazole) for Injection.

We acknowledge receipt of your submissions dated March 24, 2004 and March 30, 2004.

This supplemental new drug application provides for the following changes:

1. (b)(4)----------¯----------
2. ----------
3. additional testing sites
4. alternate test methods
5. revised specifications for the(b)(4)-------- ---------- total impurities, watercontent and pH.

We completed our review of this application, as amended and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and the submitted labeling (immediate container and carton labels submitted on March 30, 2004).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-988/S-024." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susan Daugherty, Consumer Safety Officer, at (301) 827-7456.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.
Director
Division of Gastrointestinal and
Coagulation Drug Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure: package insert

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Joyce Korvick
4/2/04 01:31:14 PM
for Dr. Robert Justice (concur with MO review of safety)